Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient populationCAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic and memory T cells associated with subsequent prolonged survival, and a beneficial effect on both injected and uninjected tumors (abscopal response)  As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile NEEDHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.

尽管进行了免疫检查点抑制剂治疗，但在进行性疾病的非小细胞肺癌患者中，两次给予CAN-2409+伐昔洛韦后，观察到中位总生存期为20.6个月，而在类似患者人群中，以多西紫杉醇为基础的标准化疗观察到的中位总生存期为11.6个月。CAN-2409治疗导致两次给予CAN-2409后全身免疫反应激活，包括与随后的延长生存期相关的循环细胞毒性和记忆T细胞数量增加，以及对注射和未注射肿瘤的有益作用（远隔反应）。截至数据截止日期，非小细胞肺癌中的CAN-2409治疗继续表现出良好的安全性和耐受性马萨诸塞州李约瑟简介，2024年5月23日（环球通讯社）——Candel Therapeutics，Inc。

(Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced topline overall survival data from its phase 2 clinical trial of CAN-2409, a multimodal biological immunotherapy candidate, plus valacyclovir (prodrug), together with standard of care (SoC) immune checkpoint inhibitor (ICI) therapy in patients with Stage III/IV non-small cell lung cancer (NSCLC) inadequately responding to ICI (anti-PD-(L)1) therapy.

（Candel或该公司）（纳斯达克：CADL），一家临床阶段的生物制药公司，专注于开发多模式生物免疫疗法以帮助患者对抗癌症，今天宣布了其CAN-2409（一种多模式生物免疫疗法候选药物）2期临床试验的总生存数据，加上伐昔洛韦（前药），以及III/IV期非小细胞肺癌（NSCLC）患者的标准治疗（SoC）免疫检查点抑制剂（ICI）治疗对ICI（抗PD-（L）1）治疗反应不足。

The data will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, May 31 to June 4, 2024, by Charu Aggarwal, MD, MPH, FASCO, Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the Perelman School of Medicine, University of Pennsylvania and Co-Principal Investigator of the clinical trial.

这些数据将于2024年5月31日至6月4日在芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会上发表，由宾夕法尼亚大学佩雷尔曼医学院肺癌卓越副教授兼临床试验联合首席研究员Charu Aggarwal，医学博士，公共卫生硕士，FASCO。

Highlights of the pr.

公关亮点。